|
|
|
| home > white papers > PhlexEview: Transforming Costly Paper Processes into Value Driven Compliance - Phlexglobal Ltd |
|
|
 WHITE PAPERS |
|
Phlexglobal Ltd
|
|
PhlexEview: Transforming Costly Paper Processes into Value Driven Compliance
|
|
Phlexglobal, the TMF experts, have developed PhlexEview, its best of breed electronic Trial Master File (eTMF) system that supports efficient management and tracking of TMF content throughout the lifecycle of a clinical trial. PhlexEview transforms costly, stagnant, paper-based processes into dynamic, value driven compliance programs by capturing, tracking and managing global TMF activities and enabling unprecedented access to trial content throughout the conduct of the study.
Compliance is always the most critical factor when designing an approach to TMF management. But that doesn’t mean that an organisation has to spend time and money managing paper that does not support global access, collaboration or compliance efforts. PhlexEview supports compliance and collaboration by leveraging industry standards and making TMF content available to users, regardless of their location.
The ability to access and view TMF content at any time transforms sluggish and inert paper processes and helps organisations to realise time and cost savings by reducing travel costs, positioning team members to proactively identify compliance issues and implement corrective actions and by facilitating global collaboration. This paper discusses some of the challenges of traditional paper-based TMFs and provides details about PhlexEview. It also suggests a new approach to TMF compliance that extracts and sets the expectation for continuing value from TMF content, rather than locking it away in paper storage where its value is minimised.
|
|
|
|
|
|
|
|
 |
News and Press Releases |
 |
High Throughput Analytics Herald a Paradigm Shift in the Development of Biopharmaceuticals
Heilbronn/Dortmund August 2019: Biopharmaceuticals have revolutionized therapies of various diseases. In particular with regard to chronical and/or severe clinical conditions like multiple sclerosis, rheumatoid arthritis or cancer they are considered the future of treatment. Also economically biological drugs are on their way up: The global biopharmaceuticals market is anticipated to reach about 400 billion USD by 2025. Which strategic alignment will help best to fill a successful pipeline?
More info >> |
|
 |
White Papers |
 |
|
Clinical Trial Labelling – More Than Just Labels
Faubel & Co. Nachfolger GmbH
Deciding which label is best for a particular trial project is not always easy. Labels have become multifunctional tools which are able to convey variable data in different languages, indicate first opening, product originality, support ease of use or blind study drugs. They are no longer used as mere carriers of specified contents.
More info >> |
|
 |
Industry Events |
 |
CPhI & P-MEC India
26-28 November 2019, India Expo Centre, Greater Noida, Delhi NCR, India
As the pharma industry looks increasingly towards India for high quality,
low cost pharma solutions, CPhI & P-MEC India is the ideal event for companies
wanting to pick up on the latest trends and innovations the market has to
offer. At CPhI & P-MEC India, you will meet the movers and shakers from
India's pharma machinery, technology and ingredients industries, giving you a
competitive advantage that will help grow your business.
More info >> |
|
|
|
